CH667590A5 - WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . - Google Patents
WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . Download PDFInfo
- Publication number
- CH667590A5 CH667590A5 CH2975/86A CH297586A CH667590A5 CH 667590 A5 CH667590 A5 CH 667590A5 CH 2975/86 A CH2975/86 A CH 2975/86A CH 297586 A CH297586 A CH 297586A CH 667590 A5 CH667590 A5 CH 667590A5
- Authority
- CH
- Switzerland
- Prior art keywords
- weight
- pharmaceutical composition
- acetyl
- composition according
- citric acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 33
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 11
- 108010011485 Aspartame Proteins 0.000 claims description 9
- 239000000605 aspartame Substances 0.000 claims description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- 235000010357 aspartame Nutrition 0.000 claims description 9
- 239000007938 effervescent tablet Substances 0.000 claims description 8
- 229960004308 acetylcysteine Drugs 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000000203 mixture Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000975 dye Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 244000248349 Citrus limon Species 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000001013 cariogenic effect Effects 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
DESCRIZIONE La N-acetil-cisteina (d'ora in avanti indicata come NAC) è un farmaco che possiede diverse favorevoli proprietà, una di queste è l'attività mucolitica. DESCRIPTION N-acetyl-cysteine (hereafter referred to as NAC) is a drug that has several favorable properties, one of which is mucolytic activity.
Per l'impiego pratico come mucolitico la NAC può essere assunta oralmente sotto forma di soluzione acquosa ottenuta per dissolvimento di un granulato o di una compressa effervescente. For practical use as a mucolytic, NAC can be taken orally in the form of an aqueous solution obtained by dissolving a granulate or an effervescent tablet.
Le proprietà organolettiche del farmaco possono tuttavia risultare soggettivamente sgradevoli. È quindi necessario attenuare il gusto tipico della NAC in caso di assunzione orale. The organoleptic properties of the drug can however be subjectively unpleasant. It is therefore necessary to attenuate the typical taste of NAC in case of oral intake.
Nelle forme farmaceutiche attualmente presenti in commercio ciò viene realizzato mediante l'aggiunta di saccarosio. In the pharmaceutical forms currently on the market this is accomplished by adding sucrose.
L'impiego di saccarosio, tuttavia, può presentare inconvenienti soprattutto per le persone che soffrono di diabete. 5 II saccarosio è inoltre uno zucchero cariogeno. The use of sucrose, however, can present drawbacks especially for people suffering from diabetes. 5 Sucrose is also a cariogenic sugar.
Da ciò la necessità di poter disporre, in alternativa alle forme farmaceutiche già esistenti, di nuove preparazioni farmaceutiche della NAC per uso orale indicate per i soggetti ai quali il saccarosio può essere nocivo. Hence the need to have, as an alternative to the already existing pharmaceutical forms, new pharmaceutical preparations of NAC for oral use indicated for subjects to whom sucrose can be harmful.
io La sostituzione del saccarosio con un dolcificante artificiale o con un edulcorante non cariogeno in una forma farmaceutica contenente NAC è un problema che a prima vista può sembrare di facile soluzione. io Replacing sucrose with an artificial sweetener or a non-cariogenic sweetener in a pharmaceutical form containing NAC is a problem that at first glance may seem easy to solve.
In realtà i problemi sono molteplici e di difficile soluzione. 15 Ad esempio è necessario che tra la NAC ed il dolcificante vi sia compatibilità chimica, che il dolcificante o l'edulcorante sia in grado di coprire od attenuare efficacemente il sapore tipico della NAC, che il gusto risultante sia comunque gradevole, che il dolcificante o l'edulcorante sia adatto alla preparazione della 20 forma farmaceutica desiderata e sia compatibile con le lavorazioni ad essa connesse. In reality, the problems are manifold and difficult to solve. 15 For example, it is necessary that there is chemical compatibility between the NAC and the sweetener, that the sweetener or sweetener is able to effectively cover or attenuate the typical flavor of the NAC, that the resulting taste is still pleasant, that the sweetener or the sweetener is suitable for the preparation of the desired pharmaceutical form and is compatible with the processes connected to it.
Abbiamo ora trovato, e forma oggetto della presente invenzione, una composizione effervescente idrosolubile contenente NAC costituita da (percentuali in peso): We have now found, and forms the subject of the present invention, a water soluble effervescent composition containing NAC consisting of (percentages by weight):
N-acetil-cisteina N-acetyl-cysteine
6-32% 6-32%
in peso by weight
Acido citrico Citric acid
35-50% 35-50%
in peso by weight
NaHCOs NaHCOs
26-37% 26-37%
in peso by weight
Aspartame Aspartame
1-1,5% 1-1.5%
in peso by weight
Aroma Aroma
5-7% 5-7%
in peso il totale essendo il 100% ed il rapporto in peso tra acido citrico ed NaHC03 essendo compreso tra 1,2 ed 1,4. by weight the total being 100% and the weight ratio between citric acid and NaHCO3 being between 1.2 and 1.4.
Ai valori più alti di NAC corrispondono i valori inferiori di 35 acido citrico e bicarbonato. The higher NAC values correspond to the lower values of 35 citric acid and bicarbonate.
Le composizioni oggetto della presente invenzione servono alla preparazione di forme farmaceutiche granulari (granulati) o di compresse effervescenti. The compositions object of the present invention serve for the preparation of granular pharmaceutical forms (granulates) or effervescent tablets.
Ambedue le forme farmaceutiche risultano prontamente so-40 lubili in acqua. Both pharmaceutical forms are readily soluble in water.
Per questioni di accettabilità da parte del consumatore del farmaco, l'impiego di un aroma può richiedere la presenza di un colorante che viene normalmente associato ad un determinato gusto. Ad esempio l'impiego di aroma di menta può richie-45 dere l'aggiunta di un colorante che impartisce un colore verde alla soluzione. For reasons of acceptability by the consumer of the drug, the use of an aroma may require the presence of a dye which is normally associated with a certain taste. For example, the use of mint flavor may require the addition of a dye which imparts a green color to the solution.
In tali casi, nella composizione può essere utile associare un quantitativo di colorante per uso farmaceutico, ad esempio in quantità comprese tra 0,5 e 1% in peso. In such cases, it may be useful in the composition to associate a quantity of dye for pharmaceutical use, for example in quantities comprised between 0.5 and 1% by weight.
so Nella seguente tabella sono riportati esempi di composizioni secondo la presente invenzione. Examples of compositions according to the present invention are reported in the following table.
TABELLA: Composizioni effervescenti idrosolubili TABLE: Water soluble effervescent compositions
A TO
B B
C C
D D
E IS
F F
G G
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
(mg) (Mg)
(%) (%)
NAC NAC
100 100
10 10
200 200
20 20
100 100
6,67 6.67
150 150
10 10
200 200
13,33 13,33
400 400
23,53 23,53
600 600
31,58 31,58
Acido citrico Citric acid
470 470
47 47
412 412
41,2 41.2
738 738
49,20 49,20
708 708
47,20 47,20
680 680
45,34 45,34
680 680
40,00 40,00
680 680
35,79 35,79
NaHCOs NaHCOs
345 345
34,5 34.5
303 303
30,3 30.3
542 542
36,13 36,13
522 522
34,80 34,80
500 500
33,33 33.33
500 500
29,41 29,41
500 500
26,32 26,32
Aspartame Aspartame
15 15
1,5 1.5
15 15
1,5 1.5
20 20
1,33 1.33
20 20
1,33 1.33
20 20
1,33 1.33
20 20
1,18 1.18
20 20
1,05 1.05
Aroma Aroma
70 70
7 7
70 70
7 7
100 100
6,67 6.67
100 100
6,67 6.67
100 100
6,67 6.67
100 100
5,88 5.88
100 100
5,26 5.26
Totale Total
1000 1000
100 100
1000 1000
100 100
1500 1500
100 100
1500 1500
100 100
1500 1500
100 100
1700 1700
100 100
1900 1900
100 100
3 3
667 590 667 590
Tra gli aromi si preferisce impiegare l'aroma di limone in quanto il colore della soluzione risultante ben si associa al gusto del limone. Among the aromas it is preferred to use the lemon aroma as the color of the resulting solution is well associated with the taste of the lemon.
In alternativa è possibile impiegare altri aromi quali ad esempio l'aroma di arancio che però é preferibile associare ad un adatto colorante arancione ad esempio ß-carotene. Alternatively, it is possible to use other aromas such as, for example, the aroma of orange which, however, is preferable to associate with a suitable orange dye such as ß-carotene.
Operando secondo normali procedure di tecnica farmaceutica le composizioni sopra illustrate vengono approntate in forma di granulati o di compresse effervescenti. Prima del confezionamento le compresse effervescenti vengono sottoposte a riscaldamento per un determinato periodo di tempo in funzione del peso e della compressa. By operating according to normal pharmaceutical technique procedures, the compositions illustrated above are prepared in the form of granulates or effervescent tablets. Before packaging, the effervescent tablets are heated for a certain period of time depending on the weight and the tablet.
I granulati vengono ripartiti in idonee bustine contenenti ciascuna 1-2 g di composizione. The granulates are divided into suitable sachets each containing 1-2 g of composition.
In alternativa si preparano compresse del peso di 1-1,2-1,5-1,7 o 1,9 g ciascuna. Alternatively, tablets weighing 1-1.2-1.5-1.7 or 1.9 g each are prepared.
Sia i granulati che le compresse effervescenti oggetto dell'invenzione si dissolvono rapidamente in acqua fornendo una soluzione acquosa di NAC di gradevole palatabilità. Both the granulates and the effervescent tablets object of the invention quickly dissolve in water providing an aqueous solution of NAC of pleasant palatability.
Con lo scopo di meglio illustrare la presente invenzione, senza tuttavia limitarla, vengono ora forniti i seguenti esempi. With the aim of better illustrating the present invention, without however limiting it, the following examples are now provided.
Esempio 1 Example 1
Un granulato costituito da: A granulate consisting of:
NAC NAC
20 20
kg kg
Acido citrico Citric acid
41,2 41.2
kg kg
NaHCOs NaHCOs
30,3 30.3
kg kg
Aspartame Aspartame
1,5 1.5
kg kg
Aroma limone Lemon flavor
7 7
kg viene preparato secondo la procedura seguente. kg is prepared according to the following procedure.
NAC ed acido citrico vengono setacciati su rete con 1,07 mm luce netta e miscelati dopo aggiunta dell'aspartame. NAC and citric acid are sieved on a net with 1.07 mm net light and mixed after addition of aspartame.
La miscela viene poi granulata in granulatore a letto fluido con acqua. Al granulato ottenuto vengono aggiunti e miscelati sodio bicarbonato ed aroma essiccato. The mixture is then granulated in a fluidized bed granulator with water. Sodium bicarbonate and dried flavor are added and mixed to the obtained granulate.
La miscela viene ripartita in bustine in accoppiata carta-al-5 luminio-politene alla dose di 1 g per bustina. The mixture is divided into sachets in laminated paper-al-5 luminio-polythene at a dose of 1 g per sachet.
In alternativa, aliquote di 1 g di miscela possono essere compresse anziché ripartite in bustine. Alternatively, 1 g aliquots of the mixture can be compressed rather than divided into sachets.
Esempio 2 Un granulato costituito da: Example 2 A granulate consisting of:
NAC NAC
60 60
kg kg
Acido citrico Citric acid
68 68
kg kg
NaHCOa NaHCOa
50 50
kg kg
Aspartame Aspartame
2 2
kg kg
Aroma arancio Orange aroma
10 10
kg viene preparato secondo la procedura seguente. kg is prepared according to the following procedure.
NAC ed acido vengono setacciati su rete con 1,07 mm luce 20 netta e miscelati dopo aggiunta dell'aspartame. NAC and acid are sieved on a net with 1.07 mm clear 20 and mixed after addition of aspartame.
La miscela viene poi granulata in granulatore a letto fluido con una soluzione acquosa di colorante El 10. The mixture is then granulated in a fluidized bed granulator with an aqueous solution of El 10 dye.
Al granulato ottenuto vengono aggiunti e miscelati sodio bicarbonato ed aroma essiccato. Sodium bicarbonate and dried flavor are added and mixed to the obtained granulate.
25 Porzioni di 1,9 g di miscela vengono poi compresse in stampi circolari del diametro di 18 mm fornendo compresse effervescenti contenenti ciascuna 600 mg di NAC. Prima del confezionamento in blisters le compresse vengono riscaldate in stufa es-siccatrice su vassoi a 70°C per 2 ore. 25 Portions of 1.9 g of mixture are then compressed in circular molds with a diameter of 18 mm providing effervescent tablets each containing 600 mg of NAC. Before blister packaging, the tablets are heated in a drying oven on trays at 70 ° C for 2 hours.
30 In alternativa la miscela può essere ripartita in bustine di accoppiata carta-alluminio-politene alla dose di 1,9 g per bustina. 30 Alternatively, the mixture can be divided into sachets of laminated paper-aluminum-polythene at a dose of 1.9 g per sachet.
Operando in maniera analoga vengono preparati granulati effervescenti o compresse effervescenti di composizione corrispondenti a quelle descritte nella tabella sopra riportata. By operating in a similar way, effervescent granules or effervescent tablets of composition corresponding to those described in the above table are prepared.
v v
Claims (8)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2975/86A CH667590A5 (en) | 1986-07-24 | 1986-07-24 | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
| DE19873723735 DE3723735A1 (en) | 1986-07-24 | 1987-07-17 | PHARMACEUTICAL, N-ACETYLCYSTONE CONTAINING WATER-SOLUBLE COMPOSITION |
| FR878710368A FR2601876B1 (en) | 1986-07-24 | 1987-07-22 | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CYSTEINE AND CITRIC ACID |
| SE8702940A SE500494C2 (en) | 1986-07-24 | 1987-07-23 | Pharmaceutical, water-soluble composition containing N-acetyl-cysteine and aspartame |
| IT21411/87A IT1222104B (en) | 1986-07-24 | 1987-07-23 | WATER SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N ACETYLYSTEINE |
| NL8701743A NL194067C (en) | 1986-07-24 | 1987-07-23 | Pharmaceutical water soluble effervescent formulation containing N-acetylcysteine and aspartame. |
| BE8700816A BE1000355A3 (en) | 1986-07-24 | 1987-07-23 | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CYSTEINE AND CITRIC ACID. |
| GB8717582A GB2192790B (en) | 1986-07-24 | 1987-07-27 | Effervescent n-acetyl cysteine compositions. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2975/86A CH667590A5 (en) | 1986-07-24 | 1986-07-24 | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH667590A5 true CH667590A5 (en) | 1988-10-31 |
Family
ID=4245841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2975/86A CH667590A5 (en) | 1986-07-24 | 1986-07-24 | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . |
Country Status (8)
| Country | Link |
|---|---|
| BE (1) | BE1000355A3 (en) |
| CH (1) | CH667590A5 (en) |
| DE (1) | DE3723735A1 (en) |
| FR (1) | FR2601876B1 (en) |
| GB (1) | GB2192790B (en) |
| IT (1) | IT1222104B (en) |
| NL (1) | NL194067C (en) |
| SE (1) | SE500494C2 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1217445B (en) * | 1988-04-29 | 1990-03-22 | Altergon Sa | SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING ACETYLCISTEIN |
| DE3822096A1 (en) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | STABILIZED DRUG PREPARATION |
| SE462779B (en) * | 1988-10-10 | 1990-09-03 | Lejus Medical Ab | PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL CYSTEIN IN A CERNA COATED WITH HYDROXIPROPYLMETHYL CELLULOS AGREEMENT |
| DE3909049A1 (en) * | 1989-03-18 | 1990-09-20 | Arthur Boskamp | PREPARATION AND THEIR USE |
| IT1231012B (en) * | 1989-07-27 | 1991-11-08 | Zambon Spa | PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING NAC. |
| DK0497724T3 (en) * | 1991-01-26 | 1996-04-29 | Senju Pharma Co | Means for the disintegration of gallstones |
| DE4103360A1 (en) * | 1991-02-05 | 1992-08-06 | Koehler Peter | Use of acetyl-cysteine and isotonic sodium chloride (0.9 per cent) - for treating bronchial asthma and bronchitis-induced spasms |
| US5296500A (en) * | 1991-08-30 | 1994-03-22 | The Procter & Gamble Company | Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy |
| IT1256616B (en) * | 1992-12-02 | 1995-12-12 | Zambon Spa | SYRUP CONTAINING N-ACETYL-CISTEIN |
| DE4406261C2 (en) * | 1993-08-31 | 1996-07-04 | Deutsches Krebsforsch | Use of thiol compounds to reduce body fat |
| BE1007926A3 (en) * | 1994-01-31 | 1995-11-21 | Zambon Int Pharma | Pharmaceutical composition containing n-acetyl-cysteine. |
| US5451405A (en) * | 1994-04-25 | 1995-09-19 | Chesebrough-Pond's Usa Co. | Skin treatment composition |
| DE19509856C2 (en) * | 1995-03-17 | 1997-09-11 | Schwabe Willmar Gmbh & Co | Use of an effervescent composition with Ginkgo biloba dry extract for the treatment of peripheral and cerebral circulatory disorders |
| CN1324234A (en) | 1998-09-25 | 2001-11-28 | 格利科克斯有限公司 | Fructosamine oxidase: antagonists and inhibitors |
| EP1115842A4 (en) | 1998-09-25 | 2002-08-21 | Glycox Corp Ltd | Fructosamine oxidase assay: methods and materials |
| WO2003077901A1 (en) | 2002-03-08 | 2003-09-25 | Protemix Corporation Limited | Preventing and/or treating cardiovascular disease and/or associated heart failure |
| CA3011023A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Composition comprising triethylenetramine salts for treating tissue damage |
| CA3050047A1 (en) | 2004-07-19 | 2006-03-16 | Philera New Zealand Limited | Synthesis of triethylenetetramines |
| TR200900881A2 (en) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Stable pharmaceutical compositions masked by taste and odor |
| TR200900882A2 (en) * | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Pharmaceutical compositions with high bioavailability, masked by taste and odor. |
| IT1399492B1 (en) | 2010-04-13 | 2013-04-19 | Alpex Pharma Sa | EFFERVESCENT PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYLCISTEIN. |
| CN102233139B (en) * | 2010-04-21 | 2012-09-05 | 重庆健能医药开发有限公司 | Acetylcysteine effervescent tablet and preparation method and application thereof |
| EP2571499A1 (en) * | 2010-05-18 | 2013-03-27 | Mahmut Bilgic | Pharmaceutical composition comprising n- acetylcysteine and a xanthine |
| CN101947211A (en) * | 2010-08-28 | 2011-01-19 | 浙江金华康恩贝生物制药有限公司 | Method for preparing acetylcysteine effervescent tablet |
| TR201104738A2 (en) * | 2011-05-16 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Pharmaceutical combination containing N-Acetylcysteine. |
| US8747894B2 (en) * | 2012-05-08 | 2014-06-10 | Alpex Pharma S.A. | Effervescent compositions containing N-acetylcysteine |
| WO2015117987A1 (en) | 2014-02-05 | 2015-08-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Effervescent formulations comprising ibuprofen and n-acetylcystein |
| CN113559078A (en) * | 2021-07-02 | 2021-10-29 | 安徽省先锋制药有限公司 | Preparation method of acetylcysteine effervescent tablets |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2470M (en) * | 1962-03-13 | 1964-04-20 | Mead Johnson & Co | Therapeutic composition. |
| ZA723683B (en) * | 1971-07-12 | 1973-06-27 | Hoffmann La Roche | Improved effervescent preparations |
| DE3317558A1 (en) * | 1983-05-13 | 1984-11-15 | Dietrich Dr.med. Sta. Eulalia Ibiza Reichert | Oral antisnoring composition |
| DE3317530A1 (en) * | 1983-05-13 | 1984-11-15 | Dietrich Dr.med. Sta. Eulalia Ibiza Reichert | Antisnoring composition |
| IT1170268B (en) * | 1983-12-21 | 1987-06-03 | Zambon Spa | USE OF ACETYLCISTEIN TO REDUCE THE INCREASE IN THE PROLIEFERATION OF THE BASAL CELLS OF THE RESPIRATORY THRACHEO-BRONCHIAL EPITHELIUM INDUCED BY TOBACCO SMOKE IN MAMMALS |
| DE3514995A1 (en) * | 1985-04-25 | 1986-10-30 | Protopharma Ltd., 7831 Malterdingen | Use of sulfhydryl pharmaceuticals for combating damage to the gastric mucosa |
-
1986
- 1986-07-24 CH CH2975/86A patent/CH667590A5/en not_active IP Right Cessation
-
1987
- 1987-07-17 DE DE19873723735 patent/DE3723735A1/en active Granted
- 1987-07-22 FR FR878710368A patent/FR2601876B1/en not_active Expired
- 1987-07-23 BE BE8700816A patent/BE1000355A3/en not_active IP Right Cessation
- 1987-07-23 NL NL8701743A patent/NL194067C/en not_active IP Right Cessation
- 1987-07-23 IT IT21411/87A patent/IT1222104B/en active
- 1987-07-23 SE SE8702940A patent/SE500494C2/en not_active IP Right Cessation
- 1987-07-27 GB GB8717582A patent/GB2192790B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2192790B (en) | 1990-01-31 |
| DE3723735C2 (en) | 1992-05-21 |
| FR2601876A1 (en) | 1988-01-29 |
| GB2192790A (en) | 1988-01-27 |
| BE1000355A3 (en) | 1988-11-08 |
| GB8717582D0 (en) | 1987-09-03 |
| SE8702940L (en) | 1988-01-25 |
| SE8702940D0 (en) | 1987-07-23 |
| NL194067B (en) | 2001-02-01 |
| NL8701743A (en) | 1988-02-16 |
| DE3723735A1 (en) | 1988-02-04 |
| IT8721411A0 (en) | 1987-07-23 |
| NL194067C (en) | 2001-06-05 |
| SE500494C2 (en) | 1994-07-04 |
| IT1222104B (en) | 1990-08-31 |
| FR2601876B1 (en) | 1989-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH667590A5 (en) | WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. . | |
| ES2263216T3 (en) | PROCEDURE FOR THE PREPARATION OF A SUITABLE GRANULATE FOR THE PREPARATION OF SOLUBLE TABLETS IN THE MOUTH QUICKLY DISGREGABLE. | |
| CH666814A5 (en) | WATER-SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. | |
| AU613517B2 (en) | Morphine-containing composition | |
| US4760094A (en) | Spray dried acetaminophen | |
| AU627194B2 (en) | Pharmaceutical compositions | |
| US20030161879A1 (en) | Tablets quickly disintegrating in mouth | |
| CH689249A5 (en) | pharmaceutical compositions of chewing gum base and process for their preparation. | |
| BG65011B1 (en) | Improved fast disintegrating tablet | |
| HUP0402154A2 (en) | Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus | |
| CA2450359A1 (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| ES2365648T3 (en) | ORAL ADMINISTRATION OF A CALCITONINE. | |
| HUP0301390A2 (en) | Oral pharmaceutical composition containing valsartan | |
| US2714083A (en) | Appetite satient | |
| KR100441179B1 (en) | Diclofenac Pharmaceutical Composition | |
| AU637773B2 (en) | Fruity flavoured nasal decongestant composition | |
| JPS5982311A (en) | Sustained release preparation of cephalexin | |
| SI21221A (en) | Quickly decomposable tablets | |
| CH674940A5 (en) | ||
| US7182964B2 (en) | Dissolving thin film xanthone supplement | |
| US5006516A (en) | Method for the prophylaxis of cardiac infarctions and the prevention of reinfarctions | |
| US20080152677A1 (en) | Oral hygiene formulations in the form of capsules | |
| UA79567C2 (en) | Orodispersible pharmaceutical composition of antithrombolic compound | |
| JP2021042152A (en) | Phosphodiesterase 5a1 activity inhibitor, muscle relaxation or contraction inhibitor, and dysuria preventive or improver | |
| CA2362757A1 (en) | Effervescent pharmaceutical formulation containing metamizole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NV | New agent |
Representative=s name: E. BLUM & CO. PATENTANWAELTE |
|
| PUE | Assignment |
Owner name: INPHARZAM INTERNATIONAL S.A. TRANSFER- INPHARZAM S |
|
| PL | Patent ceased |